The company has received regulatory approval from all government authorities for the acquisition
Pfizer has announced that it has completed the acquisition of the pharmaceutical development company, InnoPharma. The company has received regulatory approval from all US government authorities required by the agreement and other closing conditions.
"We believe this acquisition will help Pfizer build a strong sterile injectables pipeline in areas such as oncology and central nervous disorders. Sterile injectables is one of the several areas of potential growth. This acquisition reflects our continued view that attractive growth opportunities, both external and organic, exist for the business," said Mr John Young, group president, Pfizer Global Established Pharma (GEP).